Search Results 1-10 of 28371 for ������������������������������������������r���:PC53���
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's ...
The Infection and Immunity Lab of Raymund R. Razonable, M.D., at Mayo Clinic studies COVID-19 and transplant-related infections such as cytomegalovirus ...
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive.
The purpose of this study is to assess the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R ...
This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, predictive biomarkers and pharmacokinetics/ pharmacodynamics of ...
The purpose of this study is to determine safety and tolerability of orally delivered R-3750 in mild to moderate patients with ulcerative colitis. Participation ...
Subjects will be randomized 1:1 to R-CHOP plus enzastaurin or R CHOP (plus placebo during induction). All subjects will receive up to 6 cycles (3 weeks per ...
Close up of IV drip for patient and Infusion pump in hospital. ROCHESTER, Minn. — The targeted therapy everolimus may be safely combined with R-CHOP for new, ...
Klatte DCF, Starr JS, Clift KE, Hardway HD, van Hooft JE, van Leerdam ME, Potjer TP, Presutti RJ, Riegert-Johnson DL, Wallace MB, Bi Y. Utilization and ...
At Mayo Clinic, R. Scott Wright, M.D., focuses his research on improved diagnosis, treatment and patient outcomes in acute coronary syndromes and treatment ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.